Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HAEMONETICS CORP Director's Dealing 2018

Jul 30, 2018

31565_dirs_2018-07-30_4093b12c-1d42-4edc-acf6-00a8a3ced2ae.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2018-07-26

Reporting Person: MEELIA RICHARD J (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-07-26 Common Stock A 1696 Acquired 28607 Direct

Footnotes

F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant.

F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.